Zobrazeno 1 - 10
of 22
pro vyhledávání: '"D. Bruetman"'
Autor:
Ramaswamy Govindan, Rafat Ansari, Menggang Yu, A. K. Agarwala, William B. Fisher, Shadia I. Jalal, Marcus A. Neubauer, Donald A. Richards, Nasser H. Hanna, Cynthia S. Johnson, D. Bruetman, Lawrence H. Einhorn, Timothy Breen, Anton Melnyk, H. D. Riggs
Publikováno v:
Annals of Oncology. 23:1730-1738
Background Concurrent chemoradiation with etoposide and cisplatin (EP/XRT) is standard treatment for inoperable stage III locally advanced non-small-cell lung cancer (LA-NSCLC). Consolidation docetaxel (D; Taxotere) after EP/XRT resulted in increased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::062d8d9c9667c052eacb51e03a6908e5
https://doi.org/10.1093/annonc/mdr565
https://doi.org/10.1093/annonc/mdr565
Autor:
John K. Erban, B Adesunloye, Christopher R. Chitambar, S Badve, T Lee, I Shalaby, V Canfield, C Ma, M Radovich, Elisavet Paplomata, KD Miller, R Nanda, M Graham, L Aggarwal, D Bruetman, M Lippman, N Radhakrishnan, M Danso, Carla I. Falkson, Michael A. Thompson, R Langdon, Bryan J. Schneider, M McCormick, NA Reddy, B O'Neil, K Daily, Marcelo Blaya, Radhika Walling, Filipa Lynce, E Robin, P Helft
Publikováno v:
Cancer Research. 77:OT3-04
Background: About 1/3 of patients with TNBC who receive preoperative therapy will experience a pathological complete response (pCR). Patients with residual disease have a markedly inferior overall survival (OS) compared to those who experience pCR. R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe935099d33eb6279e0e11bcd4e91757
https://doi.org/10.1158/1538-7445.sabcs16-ot3-04-01
https://doi.org/10.1158/1538-7445.sabcs16-ot3-04-01
Autor:
H. J. Lenz, Jordan Berlin, Reena Patel, JieJane Liu, Manish A. Shah, C. Baker Brachmann, Johanna C. Bendell, Zev A. Wainberg, Alexander Starodub, Haeseong Park, D. Bruetman, Michael S. Gordon, Pankaj Bhargava, Jorge Chaves
Publikováno v:
Annals of Oncology. 29:viii189-viii190
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1b7f6ca007516d70a5ae8b4fa0234cb
https://doi.org/10.1093/annonc/mdy281.113
https://doi.org/10.1093/annonc/mdy281.113
Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study
Autor:
Menggang Yu, Sumeet Bhatia, Shadia I. Jalal, Gregory A. Masters, William B. Fisher, Ramaswamy Govindan, Angela White, Rafat Ansari, D. Bruetman, Daniel G. Stover, Nasser H. Hanna
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(1)
Introduction: Small cell lung cancer (SCLC) is initially a chemotherapy-sensitive disease. Nevertheless, drug-resistance results in disease recurrence in most patients. Many drugs, including antimetabolites, are active, but only minimal progress has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86b4f166a70f80bfc2d23e98dc702e25
https://pubmed.ncbi.nlm.nih.gov/19096313
https://pubmed.ncbi.nlm.nih.gov/19096313
Autor:
Constantin T. Yiannoutsos, Prasad Mantravadi, Ramaswamy Govindan, Naveed Mahfooz Chowhan, Thomas Anderson, Marcus A. Neubauer, Cynthia D. Johnson, James C. Arseneau, Angela White, William E. Fisher, Donald A. Richards, Nasser Hanna, Craig W. Reynolds, Sreenivasa Nattam, T. Breen, Rafat Ansari, Lawrence H. Einhorn, D. Bruetman, Ronald C. McGarry, Anton Melnyk
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35)
Purpose Concurrent chemoradiotherapy is standard treatment for patients with inoperable stage III non–small-cell lung cancer (NSCLC). A phase II study by the Southwest Oncology Group using consolidation docetaxel after cisplatin (P), etoposide (E),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e66d48b48a37167c899ea59ba56b68e
https://pubmed.ncbi.nlm.nih.gov/19001323
https://pubmed.ncbi.nlm.nih.gov/19001323
Autor:
L. A. Mina, M. A. Neubauer, R. H. Ansari, R. Govindan, L. H. Einhorn, W. Fisher, D. Bruetman, N. M. Chowhan, C. Johnson, N. H. Hanna
Publikováno v:
Journal of Clinical Oncology. 26:7519-7519
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1a34073a4cf9a90f56a9c3cbde29c04
https://doi.org/10.1200/jco.2008.26.15_suppl.7519
https://doi.org/10.1200/jco.2008.26.15_suppl.7519
Autor:
William E. Fisher, T. Breen, D. Bruetman, Constantin T. Yiannoutsos, Nasser H. Hanna, M. M. Sgroi, Rafat Ansari, Ramaswamy Govindan, Cynthia D. Johnson, Marcus A. Neubauer
Publikováno v:
Journal of Clinical Oncology. 25:9037-9037
9037 Background: Concurrent CRT is standard treatment for pts with unresectable stage III NSCLC. HOG LUN01–24 is a phase III trial testing if consolidation D improves survival following EP/XRT. Few data are available on outcomes in elderly pts. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53c5d34546ddeab33fdb83b2780bb772
https://doi.org/10.1200/jco.2007.25.18_suppl.9037
https://doi.org/10.1200/jco.2007.25.18_suppl.9037
Autor:
Rafat Ansari, Beth E. Juliar, Ramaswamy Govindan, Nasser H. Hanna, Lawrence H. Einhorn, Angela White, Marcus A. Neubauer, Pablo M. Bedano, D. Bruetman, T. Breen
Publikováno v:
Journal of Clinical Oncology. 24:7043-7043
7043 Background: Concurrent chemo radiotherapy is the standard treatment for pts with unresectable stage III NSCLC. A previously reported phase II study (Gandara et al J Clin Oncol 2003) suggests that consolidation D after concurrent PE/XRT may furth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fbc98fe28d89865adad7f0cbf0069a7
https://doi.org/10.1200/jco.2006.24.18_suppl.7043
https://doi.org/10.1200/jco.2006.24.18_suppl.7043
Autor:
Nasser H. Hanna, Beth E. Juliar, Sumeet Bhatia, Rafat Ansari, Ramaswamy Govindan, William E. Fisher, M. Hosford, T. Breen, D. Bruetman, Angela White
Publikováno v:
Journal of Clinical Oncology. 24:7063-7063
7063 Background: Patients with relapsed SCLC have a dismal prognosis. Pemetrexed is a well tolerated agent, which is active against non-small cell lung cancer. We postulated that Pemetrexed may also be active and well tolerated in pts with relapsed S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4af6551fda4146be58f82ed8647edc97
https://doi.org/10.1200/jco.2006.24.18_suppl.7063
https://doi.org/10.1200/jco.2006.24.18_suppl.7063
Autor:
A. K. Agarwala, D. Taber, J. McClean, Nasser H. Hanna, Michael L. Titzer, William E. Fisher, Beth E. Juliar, Lawrence H. Einhorn, T. Breen, D. Bruetman
Publikováno v:
Journal of Clinical Oncology. 24:7066-7066
7066 Background: Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway, has single agent activity in NSCLC. Preclinical studies demonstrate significant interactions between the EGFR and cyclo-oxygenase 2 (COX-2) pathways and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb7645b39d5d6f1c50f3cbdf13153ed7
https://doi.org/10.1200/jco.2006.24.18_suppl.7066
https://doi.org/10.1200/jco.2006.24.18_suppl.7066